Chemo-immuno-hormonal combination therapy for metastatic renal cell carcinoma

Medicine and Dentistry

• Combination Therapy 100%
• Patient 85%
• Medroxyprogesterone Acetate 42%
• Therapeutic Procedure 42%
• Oncology 42%
• Chemotherapy 28%
• Side Effect 28%
• Interferon 28%
• Immunoglobulin 28%
• Kidney Metastasis 28%
• Vinblastine 28%
• Survival 28%
• In Vitro 14%
• Toxicity 14%
• Neoplasm 14%
• Gene Expression 14%
• Surgery 14%
• Lymph Node 14%
• Primary Tumor 14%
• Outpatient 14%
• Distant Metastasis 14%
• Lymph Node Metastasis 14%
• Indicator 14%
• Clear Cell Renal Cell Carcinoma 14%
• Age 14%
• Radical Nephrectomy 14%
• Lung Lobectomy 14%
• Renal Cell Carcinoma Cell Line 14%
• Base 14%
• Male 14%
• Female 14%
• Kidney 14%
• Lung 14%
• Liver 14%
• Bone 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Combination Therapy 85%
• Medroxyprogesterone Acetate 42%
• Interferon 28%
• Immunoglobulin 28%
• Side Effect 28%
• Kidney Metastasis 28%
• Vinblastine 28%
• Survival 28%
• Neoplasm 14%
• Toxicity 14%
• Indicator 14%
• Primary Tumor 14%
• Distant Metastasis 14%
• Lymph Node Metastasis 14%
• Base 14%
• Death 14%